Agile Says It's On Track To Hit $25M-$30M Net Annual Revenue After A Strong Performance In Q2
Portfolio Pulse from Happy Mohamed
Agile Therapeutics (NASDAQ:AGRX) reported strong Q2 results with significant revenue growth from its birth control patch, Twirla. Net revenue from Twirla reached $5.5 million, a 44% increase over the previous quarter and a 159% increase over Q2 2022. The company also reported a decrease in operating expenses, which helped widen its gross margin. Agile is focusing on expanding access to Twirla through strategic partnerships and reaffirmed its net annual revenue target of $25 to $30 million for 2023.
August 17, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Agile Therapeutics reported strong Q2 results, driven by significant revenue growth from its birth control patch, Twirla. The company also managed to decrease its operating expenses, which helped widen its gross margin.
The strong Q2 results, driven by significant revenue growth from Twirla and decreased operating expenses, are positive indicators for Agile Therapeutics. The company's focus on expanding access to Twirla through strategic partnerships also suggests potential for continued growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100